Company news
Cipher Pharmaceuticals Inc. news in 2015
Cipher Pharmaceuticals Inc.'s news releases, calls and decks from 2015, newest first.
Cipher Receives Health Canada Approval of (Pr)Beteflam(TM)
December 7, 2015
Cipher Pharmaceuticals to present at Piper Jaffray Healthcare Conference 2015
November 25, 2015
Cipher to present at TD Securities 2015 Technology & Healthcare Conference
November 16, 2015
Cipher Reports Third Quarter Results
November 4, 2015
Notice of Cipher Pharmaceuticals Inc. Q3 2015 Conference Call
October 21, 2015
Cipher announces settlement in patent litigation for Absorica®
October 5, 2015
Cipher Reports Financial and Operational Results for Q2 2015
August 14, 2015
Cipher Pharmaceuticals announces acceptance of 510(k) submission for Dermadexin(TM) by FDA
August 4, 2015
Notice of Cipher Pharmaceuticals Inc. Q2 2015 Conference Call
July 31, 2015
Cipher Pharmaceuticals Announces Successful Completion of Second Phase III for Ozenoxacin
July 30, 2015
Cipher Pharmaceuticals to Present at 2015 JMP Securities Life Sciences Conference
June 19, 2015
Cipher Pharmaceuticals to Present at BIO International Convention
June 4, 2015
Cipher Pharmaceuticals Strengthens Leadership Team with Key Executive Appointments and Announces Launch of Vaniqa® in Canada
June 2, 2015
Cipher Pharmaceuticals to Present at Jefferies 2015 Global Healthcare Conference
May 28, 2015
Cipher Pharmaceuticals Inc. Reports Voting Results from Annual and Special Meeting of Shareholders
May 14, 2015
Cipher Reports Financial and Operational Results for Q1 2015
May 13, 2015
Cipher Pharmaceuticals Acquires Canadian Commercialization Rights to Vaniqa® and Actikerall®
May 6, 2015
Notice of Cipher Pharmaceuticals Inc. Q1 2015 Conference Call and 2014 Annual and Special Meeting of Shareholders
April 29, 2015
Cipher Pharmaceuticals announces outcome of Markman hearing in patent infringement suit for Absorica®
April 24, 2015
Cipher Pharmaceuticals to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference
April 22, 2015
Cipher Pharmaceuticals announces U.S. commercial entry through acquisition of INNOCUTIS
April 13, 2015
Cipher Pharmaceuticals to participate at Laurentian Bank Securities Annual Investor Conference
March 31, 2015
Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and rheumatoid arthritis
March 23, 2015
Cipher Pharmaceuticals to present at Cowen and Company Health Care Conference 2015
February 26, 2015
Cipher Pharmaceuticals acquires three products from Astion Pharma
February 26, 2015
Cipher Reports Financial Results for Fiscal 2014
February 25, 2015
Cipher Pharmaceuticals Announces Beteflam Patch Accepted For Review By Health Canada
February 12, 2015
Cipher Pharmaceuticals to present at BIO CEO & Investor Conference 2015
February 9, 2015
Notice of Cipher Pharmaceuticals Inc. Q4 and year-end 2014 conference call
February 3, 2015
Cipher Pharmaceuticals appoints Lynne Bulger as Vice President, Medical Affairs
January 19, 2015
Cipher Pharmaceuticals acquires assets of Melanovus Oncology Inc.
January 9, 2015
Cipher Pharmaceuticals acquires Canadian commercialization rights to novel antibacterial compound Ozenoxacin
January 7, 2015